Table 4.
Characteristics | Odds ratio | 95% CI | P value | Adjusted odds ratio | 95% CI | P value |
---|---|---|---|---|---|---|
Male gender | 0.92 | 0.56–1.50 | 0.734 | |||
Stavudine-based ART regimen | 4.18 | 2.37–7.37 | <0.001 | 4.79 | 2.45–9.38 | <0.001 |
Age | 1.03 | 0.89–1.19 | 0.696 | |||
ART duration | 1.24 | 0.95–1.63 | 0.113 | |||
Initial CD4 counts per 50 cells/μL increase | 0.99 | 0.86–1.15 | 0.932 | |||
ART start body weight | 1.02 | 0.90–1.05 | 0.115 | |||
Peak body weight >65 kgs | 1.35 | 1.03–1.75 | 0.027 | 1.44 | 1.05–1.97 | 0.023 |
Enrolment BMI <24 | 1.26 | 0.77–2.27 | 0.423 | |||
Systolic blood pressure >150 mm/Hg | 1.00 | 0.99–1.02 | 0.443 | 0.99 | 0.97–1.06 | 0.153 |
Enrolment CD4 count >200 cells/μL | 0.90 | 0.49–1.64 | 0.734 | |||
Abnormal waist to hip ratio+ | 1.23 | 0.73–2.07 | 0.446 | 1.14 | 0.63–2.05 | 0.673 |
Family history of hypertension | 1.75 | 1.02–2.98 | 0.04 | 1.44 | 0.79–2.64 | 0.235 |
Family history of diabetes mellitus | 2.29 | 1.05–4.97 | 0.037 | |||
Lipodystrophy | 2.77 | 1.28–5.99 | 0.01 | 1.60 | 0.61–4.21 | 0.338 |
WHO stage III and IV | 1.21 | 0.71–2.08 | 0.487 |
CI: confidence interval; ART: antiretroviral treatment; BMI: body mass index; WHO: World Health Organization.
+WHR defined abnormal if >0.94 for males and >0.8 for females.